Thymosin Alpha-1 Reviews

Sources · The literature

Thymosin Alpha-1 References

Every citation used across this site, with DOIs and PubMed identifiers.

Back to the researchAbout this appraisal

The cited record

These are the primary sources behind the Thymosin Alpha-1 appraisal on this site. Each carries a DOI or PubMed identifier so the claim can be verified at the source. The list spans the foundational characterization, the mechanism work, the sepsis and COVID-19 trials, the hepatitis B meta-analyses, and the autoimmune-tolerance studies that anchor this site's lens. Where the literature is heterogeneous or a result was null, the body pages say so explicitly rather than smoothing it over.

  1. Goldstein AL, Low TL, McAdoo M, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci U S A. 1977;74(2):725-729. ↗
  2. Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013;17(1):R8. ↗
  3. Wu J, Pei F, Zhou L, et al. The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025;388:e082583. ↗
  4. Dominari A, Hathaway III D, Pandav K, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020;9(5):67-78. ↗
  5. Romani L, Bistoni F, Montagnoli C, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006;108(7):2265-2274. ↗
  6. Liu Y, Pan Y, Hu Z, et al. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clin Infect Dis. 2020;71(16):2150-2157. ↗
  7. Costantini C, Bellet MM, Pariano M, et al. A Reappraisal of Thymosin Alpha1 in Cancer Therapy. Front Oncol. 2019;9:873. ↗
  8. Pica F, Chimenti MS, Gaziano R, et al. Serum thymosin alpha1 levels in patients with chronic inflammatory autoimmune diseases. Clin Exp Immunol. 2016;186(1):39-45. ↗
  9. Baxevanis CN, Reclos GJ, Perez S, Kokkinopoulos D, Papamichail M. Immunoregulatory effects of fraction 5 thymus peptides. I. Thymosin alpha 1 enhances while thymosin beta 4 suppresses the human autologous and allogeneic mixed lymphocyte reaction. Immunopharmacology. 1987;13(2):133-141. ↗
  10. Hou F, Huang JM, Zhang R, Li L, Li G. [An experimental study on the regulation of bone marrow-derived mesenchymal stem cells through indoleamine 2,3-dioxygenase signaling pathway by thymosin alpha1 for improving the immunosuppression mediated by T cell]. Zhonghua Er Ke Za Zhi. 2011;49(3):181-185. ↗
  11. Giacomini E, Rizzo F, Etna MP, et al. Thymosin-α1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients. Mult Scler. 2018;24(2):127-139. ↗
  12. Renga G, Bellet MM, Pariano M, et al. Thymosin α1 protects from CTLA-4 intestinal immunopathology. Life Sci Alliance. 2020;3(10):e202000662. ↗
  13. Yang YF, Zhao W, Zhong YD, et al. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol J. 2009;6:63. ↗
  14. Htet NH, Naing C, Vongpunsawad S, Win TT, Poovorawan Y. Thymosin-alpha-1 for people with chronic hepatitis B (Cochrane systematic review protocol). Cochrane Database Syst Rev. 2022;3:CD014610. ↗
  15. Ricci D, Etna MP, Severa M, et al. Novel evidence of Thymosin α1 immunomodulatory properties in SARS-CoV-2 infection: Effect on innate inflammatory response in a peripheral blood mononuclear cell-based in vitro model. Int Immunopharmacol. 2023;117:109996. ↗